AGP
Artia Global Partners Portfolio holdings
AUM
$389M
This Quarter Return
+5.68%
1 Year Return
+34.68%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$249M
AUM Growth
+$249M
(-4.6%)
Cap. Flow
-$16.9M
Cap. Flow
% of AUM
-6.79%
Top 10 Holdings %
Top 10 Hldgs %
79.38%
Holding
36
New
10
Increased
6
Reduced
7
Closed
2
Top Buys
| 1 |
Biogen
BIIB
|
$13.9M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$8.78M |
| 3 |
Merck
MRK
|
$6.92M |
| 4 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$3.64M |
| 5 |
AstraZeneca
AZN
|
$1.7M |
Top Sells
| 1 |
Eli Lilly
LLY
|
$26.6M |
| 2 |
argenx
ARGX
|
$18.2M |
| 3 |
Novo Nordisk
NVO
|
$7.96M |
| 4 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$2.46M |
| 5 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$2.43M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Novo Nordisk
NVO
$251B
| $51.1M | 18.88% |
321,055
-50,000
| -13% | -$7.96M |
|
|
2
Merck
MRK
$210B
| $35M | 12.94% |
329,200
+65,000
| +25% | +$6.92M |
|
|
3
Biogen
BIIB
$19.4B
| $22.2M | 8.22% |
80,000
+50,000
| +167% | +$13.9M |
|
|
KRTX
4
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $16.1M | 5.96% |
88,831
-10,436
| -11% | -$1.9M |
|
5
AbbVie
ABBV
$372B
| $14.5M | 5.35% |
90,821
| – | – |
|
|
6
argenx
ARGX
$43.6B
| $13.6M | 5.01% |
36,404
-48,800
| -57% | -$18.2M |
|
7
Moderna
MRNA
$9.37B
| $13M | 4.81% |
84,719
+10,000
| +13% | +$1.54M |
|
|
8
BioMarin Pharmaceuticals
BMRN
$11.2B
| $11.5M | 4.26% |
118,465
+90,248
| +320% | +$8.78M |
|
|
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
| $10.4M | 3.83% |
51,175
| – | – |
|
|
ISEE
10
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $9.84M | 3.64% |
404,615
-100,000
| -20% | -$2.43M |
|
|
11
Eli Lilly
LLY
$657B
| $9.25M | 3.42% |
26,928
-77,400
| -74% | -$26.6M |
|
|
12
AstraZeneca
AZN
$248B
| $7.1M | 2.62% |
102,307
+24,548
| +32% | +$1.7M |
|
13
BioNTech
BNTX
$24B
| $4.62M | 1.71% |
37,108
| – | – |
|
14
Neurocrine Biosciences
NBIX
$13.8B
| $4.55M | 1.68% |
45,000
| – | – |
|
|
RETA
15
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $3.64M | 1.34% |
+40,000
| New | +$3.64M |
|
16
Alnylam Pharmaceuticals
ALNY
$58.5B
| $3.2M | 1.18% |
15,971
| – | – |
|
17
Thermo Fisher Scientific
TMO
$186B
| $2.93M | 1.08% |
5,088
| – | – |
|
|
ITCI
18
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $2.25M | 0.83% |
41,600
| – | – |
|
19
Vertex Pharmaceuticals
VRTX
$100B
| $2.24M | 0.83% |
7,114
| – | – |
|
|
VRNA
20
Verona Pharma
VRNA
$9.16B
| $1.82M | 0.67% |
90,451
+50,500
| +126% | +$1.01M |
|
|
CBAY
21
DELISTED
Cymabay Therapeutics
CBAY
| $1.48M | 0.55% |
+169,277
| New | +$1.48M |
|
22
Charles River Laboratories
CRL
$8.04B
| $1.39M | 0.52% |
+6,905
| New | +$1.39M |
|
23
Roivant Sciences
ROIV
$8.15B
| $1.16M | 0.43% |
+157,763
| New | +$1.16M |
|
24
Viking Therapeutics
VKTX
$3.04B
| $1.14M | 0.42% |
68,408
-62,505
| -48% | -$1.04M |
|
25
FibroGen
FGEN
$47.8M
| $966K | 0.36% |
+51,795
| New | +$966K |
|